<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: Investors ", fill: "#000080"},
{source: "2: Investors ", target: "2: should carefully", fill: "#000080"},
{source: "2: should carefully", target: "2: following factors among others", fill: "#000080"},
{source: "2: following factors among others", target: "2: operations", fill: "#000080"},
{source: "2: operations", target: "2: sufficient cash resources available", fill: "#000080"},
{source: "2: sufficient cash resources available", target: "2: current level", fill: "#000080"},
{source: "2: current level", target: "2: activities through", fill: "#000080"},
{source: "2: activities through", target: "2: third quarter", fill: "#000080"},
{source: "2: third quarter", target: "2: Phase III ", fill: "#000080"},
{source: "2: Phase III ", target: "2: clinical trial program", fill: "#000080"},
{source: "2: clinical trial program", target: "2: lead product", fill: "#000080"},
{source: "2: Investors ", target: "3: requirements", fill: "#0abab5"},
{source: "3: requirements", target: "3: development", fill: "#0abab5"},
{source: "3: development", target: "3: commercialization", fill: "#0abab5"},
{source: "3: commercialization", target: "3: further optimize operations", fill: "#0abab5"},
{source: "3: requirements", target: "5: Although ", fill: "#ffa500"},
{source: "5: Although ", target: "5: common stock", fill: "#ffa500"},
{source: "5: common stock", target: "5: future equity", fill: "#ffa500"},
{source: "5: future equity", target: "5: fundraising would", fill: "#ffa500"},
{source: "5: Although ", target: "9: license compounds", fill: "#ffa343"},
{source: "9: license compounds", target: "9: technology", fill: "#ffa343"},
{source: "9: technology", target: "9: internally until", fill: "#ffa343"},
{source: "9: internally until", target: "9: potentially", fill: "#ffa343"},
{source: "9: license compounds", target: "10: raise additional funds through collaborations", fill: "#f56991"},
{source: "10: raise additional funds through collaborations", target: "10: licensing arrangements", fill: "#f56991"},
{source: "10: licensing arrangements", target: "10: relinquish", fill: "#f56991"},
{source: "10: relinquish", target: "10: technologies", fill: "#f56991"},
{source: "10: technologies", target: "10: grant licenses on unfavorable terms", fill: "#f56991"},
{source: "10: raise additional funds through collaborations", target: "41: On December ", fill: "#138808"},
{source: "41: On December ", target: "41: December ", fill: "#138808"},
{source: "41: December ", target: "41: acquisition", fill: "#138808"},
{source: "41: acquisition", target: "41: accumulated deficit", fill: "#138808"},
{source: "41: On December ", target: "START_HERE", fill: "#138808"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Humanitarian</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. It is an emerging industry that uses technology to improve activities in finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_management">Technology management</a></td>
      <td>Technology management is a set of management disciplines that allows organizations to manage their technological fundamentals to create customer advantage. Typical concepts used in technology management are:\n\nTechnology strategy (a logic or role of technology in organization),\nTechnology forecasting (identification of possible relevant technologies for the organization, possibly through technology scouting),\nTechnology roadmap (mapping technologies to business and market needs), and\nTechnology project portfolio (a set of projects under development) and technology portfolio (a set of technologies in use).The role of the technology management function in an organization is to understand the value of certain technology for the organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agilent_Technologies">Agilent Technologies</a></td>
      <td>Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><font color="blue"><font color="blue">Investors </font>    </font><font color="blue">should carefully</font> consider the following factors, <font color="blue">among others</font>, relating to     <font color="blue">Clinical Data</font>:     Risk factors relating to our business and <font color="blue">operations</font>     We do not have <font color="blue"><font color="blue">sufficient cash</font> resources available</font> to fund our <font color="blue">current level</font>     of  <font color="blue">activities through</font> the end of the <font color="blue">third quarter</font> of fiscal 2007 and     beyond, including our <font color="blue">Phase III </font><font color="blue"><font color="blue">clinical trial</font> program</font> for our <font color="blue">lead product</font>     candidate,  vilazodone</td>
    </tr>
    <tr>
      <td>Over  the  near-term, we will need to satisfy     substantial   capital  <font color="blue">requirements</font>  to  pursue  our  <font color="blue">development</font>  and     <font color="blue">commercialization</font> strategies and to further optimize <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>At currently projected rates of <font color="blue">expenditure</font>, we believe that <font color="blue">additional</font>     funding will be required to operate the Company and its new <font color="blue">subsidiaries</font>     through the end of the <font color="blue">third quarter</font> of fiscal 2007, including the funding     of  <font color="blue">Phase III </font><font color="blue"><font color="blue">clinical trial</font>s</font> for our lead drug candidate, vilazodone</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  completed  a  private  placement  of our <font color="blue">common stock</font> of     <font color="blue">approximately</font> dlra17dtta0 million in June 2006, there can be no assurance that any     <font color="blue">future equity</font> or other <font color="blue">fundraising would</font> be successful</td>
    </tr>
    <tr>
      <td>A <font color="blue">general lack</font> of     <font color="blue">market interest</font> in <font color="blue">providing further financing</font> to <font color="blue">life sciences companies</font>     could have a material adverse effect on our ability to <font color="blue">raise funds</font></td>
    </tr>
    <tr>
      <td>If we do     secure <font color="blue">additional</font> capital through a public or <font color="blue"><font color="blue">private equity</font> offering</font>,     dilution to our <font color="blue">then existing shareholders may</font> result</td>
    </tr>
    <tr>
      <td>If we are unable to secure <font color="blue">additional</font> funds when we need them, we may be     required to delay, reduce or eliminate some or all of our programs</td>
    </tr>
    <tr>
      <td>We may     also be forced to <font color="blue">license compounds</font> or <font color="blue">technology</font> to others that we would     prefer to develop <font color="blue">internally until</font> a later, and <font color="blue">potentially</font> more lucrative,     stage</td>
    </tr>
    <tr>
      <td>If we are required to raise <font color="blue">additional</font> funds through <font color="blue">collaboration</font>s     and other <font color="blue">licensing <font color="blue">arrangements</font></font>, we may have to <font color="blue">relinquish</font> our rights to     some of our <font color="blue">technologies</font> or <font color="blue">grant licenses on unfavorable terms</font></td>
    </tr>
    <tr>
      <td>Over  the  near-term,  our future capital <font color="blue">requirements</font> to continue the     <font color="blue">development</font> and <font color="blue">enhancement</font> of our <font color="blue">technologies</font>, capture market share, in     license  and  develop  genetic  tests  and  to  seek  to  complete the     <font color="blue">commercialization</font> of our drug <font color="blue">candidates</font> will be substantial and will be     influenced by many factors</td>
    </tr>
    <tr>
      <td>Such factors include the amount of milestone     payments  which we may receive under <font color="blue">collaboration</font>, licensing or other     <font color="blue">agreements</font>, the progress and cost of research and <font color="blue">development</font> projects,     <font color="blue">especially</font> the <font color="blue">Phase III </font>program for vilazodone, our <font color="blue">lead product</font> candidate,     and <font color="blue">expenses which may</font> be required for the filing, defense and <font color="blue">enforcement</font>     of <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">secure adequate financing over</font> the     near-term,  we  will not be able to pursue our product <font color="blue">development</font> and     <font color="blue">commercialization</font> strategies as currently planned</td>
    </tr>
    <tr>
      <td>-30-       _________________________________________________________________    [65]Table of <font color="blue">Contents       </font>We are <font color="blue">currently seeking</font> a <font color="blue">partner with which</font> to design and conduct a Phase     III <font color="blue">clinical program</font> for vilazodone, as we have neither the experience     <font color="blue"><font color="blue">necessary</font> nor <font color="blue">sufficient cash</font></font> to complete such a <font color="blue">clinical program</font></td>
    </tr>
    <tr>
      <td>We have limited experience in designing and conducting <font color="blue"><font color="blue">clinical trial</font>s</font>,     <font color="blue">especially</font> <font color="blue">Phase III </font><font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We also do not have <font color="blue">sufficient cash</font>     with  which to complete <font color="blue">Phase III </font><font color="blue">clinical trails</font> for vilazodone</td>
    </tr>
    <tr>
      <td>As a     result,  with  respect  to  our <font color="blue">Phase III </font>program for our <font color="blue">lead product</font>     candidate, vilazodone, we are <font color="blue">currently seeking</font> a <font color="blue">partner with which</font> to     design,  fund and conduct <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We may not be successful in     finding a <font color="blue"><font color="blue">collaboration</font> partner</font> or in designing, funding and conducting the     <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Any delay or <font color="blue">failure on</font> our or our partner’s part could     have a material adverse effect on our prospects for completing the trial and     <font color="blue">eventually</font>  developing  a  <font color="blue">commercial product</font> and, accordingly, on our     <font color="blue">prospects generally</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">biopharmaceutical</font> or <font color="blue">diagnostic</font> product <font color="blue">candidates</font> must undergo rigorous     <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">regulatory</font> approvals, which could substantially delay or     prevent their <font color="blue">development</font> or marketing</td>
    </tr>
    <tr>
      <td>Any <font color="blue">biopharmaceutical</font> and some of our <font color="blue"><font color="blue">diagnostic</font> products</font> that we develop     will be subject to rigorous <font color="blue"><font color="blue">clinical trial</font>s</font> and an extensive <font color="blue">regulatory</font>     <font color="blue">approval process implemented by</font> the FDA and <font color="blue">analogous</font> foreign <font color="blue">regulatory</font>     agencies</td>
    </tr>
    <tr>
      <td>This approval process is <font color="blue">typically lengthy</font> and expensive, and     approval is <font color="blue">never certain</font></td>
    </tr>
    <tr>
      <td>Positive results from pre-clinical studies and     <font color="blue"><font color="blue">clinical trial</font>s</font> do not ensure positive results in late stage <font color="blue"><font color="blue">clinical trial</font>s</font>     designed to <font color="blue">permit application</font> for <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>We do not know when,     or if, our current <font color="blue"><font color="blue">clinical trial</font>s</font> for <font color="blue">vilazodone will</font> be completed</td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>factors  affect  patient enrollment, including the size of the patient     population, the proximity of patients to <font color="blue">clinical sites</font>, the <font color="blue">eligibility</font>     criteria for the trial, alternative therapies, competing <font color="blue"><font color="blue">clinical trial</font>s</font> and     <font color="blue">new drugs approved</font> for the <font color="blue">conditions</font> we are <font color="blue">investigating</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">delays may increase</font> our costs and slow down our product     <font color="blue">development</font> and the <font color="blue">regulatory</font> approval process</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font>     <font color="blue">costs will also increase</font> if we need to perform more or <font color="blue">larger clinical</font>     <font color="blue">trials than</font> planned</td>
    </tr>
    <tr>
      <td>The occurrence of any of these <font color="blue">events will delay</font> our     ability to <font color="blue">generate revenue from <font color="blue">product sales</font></font> and impair our ability to     <font color="blue">become profitable</font>, which may cause us to have insufficient <font color="blue">capital resources</font>     to support our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Because of the risks and <font color="blue">uncertainties</font> in <font color="blue">biopharmaceutical</font> <font color="blue">development</font>,     products that we or our <font color="blue">collaborators</font> develop could take a <font color="blue"><font color="blue">significant</font>ly</font>     longer time to gain <font color="blue">regulatory</font> approval than we expect or <font color="blue">may never gain</font>     approval</td>
    </tr>
    <tr>
      <td>If  we  or our <font color="blue">collaborators</font> do not receive these <font color="blue">necessary</font>     approvals, we will not be able to generate substantial product or royalty     revenues  and  may not <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We and our <font color="blue">collaborators</font> may     encounter <font color="blue">significant</font> delays or excessive costs in our efforts to secure     <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>Factors that <font color="blue">raise <font color="blue">uncertainty</font></font> in obtaining these     <font color="blue">regulatory</font> approvals include the following:       •   we must demonstrate through <font color="blue"><font color="blue">clinical trial</font>s</font> that the <font color="blue">proposed product</font>     is safe and <font color="blue">effective</font> for its <font color="blue">intended use</font>;         •   we have limited experience in conducting the <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">necessary</font>     to obtain <font color="blue">regulatory</font> approval; and          •     data  obtained  from pre-clinical and <font color="blue">clinical activities</font> are     susceptible to varying <font color="blue">interpretation</font>s, which could delay, limit or prevent     <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>authorities may delay, suspend or terminate <font color="blue"><font color="blue">clinical trial</font>s</font> at     any time if they believe that the <font color="blue">patients participating</font> in trials are being     exposed to unacceptable <font color="blue">health risks</font> or if they <font color="blue">find deficiencies</font> in the     <font color="blue"><font color="blue">clinical trial</font> procedures</font></td>
    </tr>
    <tr>
      <td>In addition, our or our <font color="blue">collaborators</font>’ failure to     comply  with applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> may result in criminal     prosecution, civil penalties and other actions that <font color="blue">could impair</font> our ability     to conduct our business</td>
    </tr>
    <tr>
      <td>We  initiated a pivotal <font color="blue">Phase III </font><font color="blue">clinical trial</font> of vilazodone for the     treatment of <font color="blue">depression</font> in <font color="blue">February </font>2006</td>
    </tr>
    <tr>
      <td>We will need to complete this     <font color="blue">Phase III </font>trial before filing an NDA for marketing approval of this product     in this <font color="blue">indication</font>; we believe the NDA could be filed by the first half of     calendar 2009</td>
    </tr>
    <tr>
      <td>This <font color="blue">clinical trial</font> may be delayed for any of the reasons     described above, and may take <font color="blue">longer than</font> anticipated to initiate and/or to     complete</td>
    </tr>
    <tr>
      <td>-31-       _________________________________________________________________    [66]Table of <font color="blue">Contents       </font>We recently acquired both <font color="blue">Genaissance </font>Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>and Icoria,     Inc, each of which has historically incurred <font color="blue">significant</font> net losses, and we     expect to <font color="blue">incur net losses</font> for some time</td>
    </tr>
    <tr>
      <td><font color="blue">On <font color="blue">December </font></font>20, 2005, we completed the <font color="blue">acquisition</font> of Icoria, which has a     history  of  incurring  net  losses, and had an <font color="blue">accumulated deficit</font> of     <font color="blue">approximately</font> dlra106dtta3 million as of <font color="blue">December </font>20, 2005</td>
    </tr>
    <tr>
      <td>Genaissance, which we     acquired on October 6, 2005, had an <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font>     dlra244dtta0 million  as  of  October 6, 2005</td>
    </tr>
    <tr>
      <td>We expect that as a result of     combining our <font color="blue">operations</font> with those of our recently acquired <font color="blue">subsidiaries</font>,     we <font color="blue">will continue</font> to <font color="blue">incur net losses</font>, that it is possible that we may never     <font color="blue">generate sufficient revenue</font> to <font color="blue">become profitable</font> and that we may not sustain     <font color="blue">profitability</font> if we do <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue"><font color="blue">entering into</font> new</font> business areas and may not have the expertise,     experience and resources to pursue all of our <font color="blue"><font color="blue">businesses</font> at once</font></td>
    </tr>
    <tr>
      <td>Individually, each of <font color="blue">Clinical Data</font>, Genaissance, <font color="blue">Genome Express </font>and <font color="blue">Icoria     </font>has had experience in their <font color="blue">respective areas</font> of expertise, but we have never     pursued all of the facets of these <font color="blue"><font color="blue">businesses</font> at once</font></td>
    </tr>
    <tr>
      <td>As a result, we may     not have the experience, the <font color="blue">appropriate</font> expertise, or the resources to     pursue all <font color="blue">businesses</font> in our <font color="blue">combined company</font> and we <font color="blue">may discover</font> that some     of  the new facets of the combined business are not what we <font color="blue">previously</font>     believed and are not <font color="blue">financially viable</font></td>
    </tr>
    <tr>
      <td>Due to recent merger activity, it may be more <font color="blue">difficult</font> to obtain <font color="blue">additional</font>     financing at favorable terms, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we have not been tested as an integrated enterprise, and as a     <font color="blue">combined company</font> we have a <font color="blue">significant</font> history of losses, it may be more     <font color="blue">difficult</font>  to  encourage  <font color="blue">investment</font> in our <font color="blue">company through public</font> and     <font color="blue">additional</font> private stock offerings, <font color="blue">arrangements</font> with corporate partners,     credit <font color="blue">facilities</font> or from other sources</td>
    </tr>
    <tr>
      <td>We may never realize enhanced     liquidity in the <font color="blue">public markets</font> because the overhang in the <font color="blue">public markets</font>     as a result of recent merger <font color="blue">transaction</font>s may dissuade new investors</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">integrate successfully</font> the <font color="blue">businesses</font> of Genaissance,     <font color="blue">Genome Express </font>and Icoria with our own business</td>
    </tr>
    <tr>
      <td>During fiscal year 2006, we <font color="blue">consummated <font color="blue">mergers with</font></font> Genaissance, Genome     Express and Icoria</td>
    </tr>
    <tr>
      <td>This <font color="blue">integration</font> of all these <font color="blue"><font color="blue">businesses</font> with</font> our own     will  require  <font color="blue">significant</font>  efforts  from  <font color="blue">each company</font>, including the     <font color="blue">coordination</font>  of  product <font color="blue">development</font>, sales and <font color="blue">marketing efforts</font> and     <font color="blue">administrative</font>  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  may  find  it  <font color="blue">difficult</font> to integrate     <font color="blue">simultaneously</font> the <font color="blue">operations</font> of Genaissance, <font color="blue">Genome Express </font>and Icoria</td>
    </tr>
    <tr>
      <td>We     have <font color="blue">employees widely dispersed across</font> our <font color="blue">operations</font> in Massachusetts,     Rhode Island, Connecticut, California, Texas, North Carolina, Pennsylvania     and other domestic and foreign locations, which will increase the <font color="blue">difficult</font>y     of <font color="blue">integrating</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Genaissance, <font color="blue">Genome Express </font>and Icoria personnel     may leave their <font color="blue">respective companies</font> or our <font color="blue">combined company</font> because of the     <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>Genaissance, <font color="blue">Genome Express </font>and Icoria customers, <font color="blue"><font color="blue">distributor</font>s</font>     or  <font color="blue">suppliers may delay</font> or defer purchasing decisions, terminate their     <font color="blue">arrangements</font> with the <font color="blue">respective company</font> or our <font color="blue">combined company</font>                                        -32-       _________________________________________________________________    [67]Table of <font color="blue">Contents       </font>or demand amended terms to these <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Any of these actions by     customers, <font color="blue"><font color="blue">distributor</font>s</font> or suppliers could <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">challenges involved</font> in this <font color="blue">integration</font> include, but are not limited to,     the following:       •   retaining <font color="blue">existing customers</font> and <font color="blue">strategic partners</font> of <font color="blue">each company</font>;         •   retaining and <font color="blue"><font color="blue">integrating</font> <font color="blue">management</font></font> and other <font color="blue">key employees</font>;         •   <font color="blue">coordinating</font> research and <font color="blue">development</font> activities to enhance     <font color="blue">introduction</font> of <font color="blue">new products</font> and <font color="blue">technologies</font>, <font color="blue">especially</font> in light of     <font color="blue"><font color="blue">rapidly evolving</font> markets</font> for those products and <font color="blue">technologies</font>;          •     preserving  the  value  of  <font color="blue">various research</font> and <font color="blue">development</font>,     <font color="blue">collaboration</font>,   <font color="blue">distribution</font>,   <font color="blue">manufacturing</font>   and  other  important     <font color="blue"><font color="blue">relationship</font>s</font>;         •   <font color="blue">coordinating</font> the headquarter <font color="blue">operations</font> of <font color="blue">Genome Express </font>in France,     as well as its research and <font color="blue">development</font> <font color="blue">facilities</font> in France, which are     <font color="blue">geographically distant from</font> the <font color="blue">operations</font> of our <font color="blue">corporate headquarters</font> and     most of our <font color="blue">subsidiaries</font> in the <font color="blue">United States</font>;          •   <font color="blue">effective</font>ly managing the diversion of <font color="blue"><font color="blue">management</font> attention from</font>     business matters to <font color="blue">integration</font> issues;         •   <font color="blue">combining <font color="blue">product offerings</font></font> and <font color="blue">incorporating</font> acquired <font color="blue">technology</font> and     rights into <font color="blue">product offerings</font> <font color="blue">effective</font>ly and quickly;         •   <font color="blue"><font color="blue">integrating</font> sales efforts</font> so that customers can do business easily     with us;         •   <font color="blue">coordinating</font> and combining <font color="blue">international</font> <font color="blue">operations</font>, <font color="blue"><font color="blue">relationship</font>s</font> and     <font color="blue">facilities</font>, which may be subject to <font color="blue">additional</font> constraints imposed by local     laws and <font color="blue">regulations</font>;         •   <font color="blue">persuading employees</font> that the business cultures of <font color="blue">Clinical Data</font>,     Genaissance, <font color="blue">Genome Express </font>and Icoria are compatible;         •   <font color="blue">effective</font>ly offering products of <font color="blue">Clinical Data</font>, Genaissance, Genome     Express and Icoria to each other’s customers;         •   anticipating the market needs and achieving market <font color="blue">acceptance</font> of     <font color="blue">Clinical Data</font>, Genaissance, <font color="blue">Genome Express </font>and Icoria products;          •    <font color="blue">bringing together</font> the companies’ <font color="blue">marketing efforts</font> so that the     industry receives useful information about the <font color="blue">acquisition</font>s and customers     perceive value in our products; and         •   developing and maintaining uniform standards, controls, procedures,     and policies</td>
    </tr>
    <tr>
      <td>Our <font color="blue">acquisition</font> of Genome Express, and our <font color="blue">mergers with</font> <font color="blue">Genaissance </font>and     Icoria may fail to achieve expected <font color="blue">beneficial synergies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Clinical  </font>Data  acquired  <font color="blue">Genome Express </font>with the <font color="blue">expectation</font> that the     <font color="blue">acquisition</font> will result in <font color="blue">beneficial synergies</font>, such as cost reductions and     a  broader  suite of products and services to offer to our current and     <font color="blue">targeted customers</font></td>
    </tr>
    <tr>
      <td>We also expect to achieve similar <font color="blue">beneficial synergies</font>     in our recently completed <font color="blue">mergers with</font> <font color="blue">Genaissance </font>and Icoria</td>
    </tr>
    <tr>
      <td><font color="blue">Achieving     </font>these  anticipated synergies and the <font color="blue">potential benefits underlying</font> our     reasons for <font color="blue">entering into</font> the <font color="blue">acquisition</font>s will depend on the success of     <font color="blue">integrating</font> all four companies’ <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>It is not certain that we can     <font color="blue">successfully integrate</font> Genaissance, <font color="blue">Genome Express </font>and Icoria in a timely     manner or at all, or that any of the anticipated <font color="blue">benefits will</font> be realized</td>
    </tr>
    <tr>
      <td>Risks from <font color="blue">unsuccessful</font> <font color="blue">integration</font> of all the companies include:       •   the <font color="blue">potential disruption</font> of ongoing business and <font color="blue">distraction</font> of our     <font color="blue">management</font>;         •   the risk that it may be more <font color="blue">difficult</font> to retain key <font color="blue">management</font>,     marketing, and <font color="blue">technical personnel</font> after the <font color="blue">acquisition</font>s;          •     the risk that costs and <font color="blue">expenditure</font>s for retaining personnel,     eliminating un<font color="blue">necessary</font> resources and <font color="blue">integrating</font> the <font color="blue">businesses</font> are greater     than anticipated;         •   the risk that we <font color="blue">cannot increase sales</font> of our products; and         •   the risk that <font color="blue">integrating</font> and changing our <font color="blue">businesses</font> will impair our     <font color="blue"><font color="blue">relationship</font>s</font> with our <font color="blue">existing customers</font> and business partners</td>
    </tr>
    <tr>
      <td>-33-       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>Even if we are able to integrate <font color="blue">operations</font>, there can be no assurance that     the  synergies  we  hope  for  will be achieved or that <font color="blue">integration</font> of     Genaissance, <font color="blue">Genome Express </font>or Icoria will not disrupt or <font color="blue">eliminate such</font>     synergies</td>
    </tr>
    <tr>
      <td>The failure to achieve such synergies could <font color="blue">adversely</font> affect our     business and results of <font color="blue">operations</font>, including use of cash in <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Because a <font color="blue">significant</font> portion of our <font color="blue">total assets</font> will be represented by     goodwill and other <font color="blue">intangible assets</font> that are subject to <font color="blue">mandatory annual</font>     <font color="blue"><font color="blue">impairment</font> evaluations</font>, we could be required to write-off some or all of     this  goodwill  and  other <font color="blue">intangibles</font>, which may <font color="blue">adversely</font> affect our     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We accounted for the <font color="blue">acquisition</font>s of Genaissance, <font color="blue">Genome Express </font>and <font color="blue">Icoria     </font>using the <font color="blue">purchase method</font> of <font color="blue">accounting</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">purchase prices</font> for these     <font color="blue">businesses</font> were allocated to <font color="blue">identifiable tangible</font> and <font color="blue">intangible assets</font> and     assumed  <font color="blue">liabilities</font>  based  on  estimated  <font color="blue"><font color="blue">fair value</font>s at</font> the date of     <font color="blue">consummation</font> of the <font color="blue">respective mergers</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">unallocated portions</font> of the     <font color="blue">purchase prices</font> were allocated to goodwill</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>47dtta9prca of our total     assets  at March 31, 2006 are goodwill and other <font color="blue">intangibles</font>, of which     <font color="blue">approximately</font> dlra27dtta5 million are goodwill</td>
    </tr>
    <tr>
      <td>In <font color="blue">accordance with</font> SFAS Nodtta 142,     goodwill is not <font color="blue">amortized but</font> is <font color="blue">reviewed annually</font> or more <font color="blue">frequently</font> if     <font color="blue"><font color="blue">impairment</font> indicators</font> arise</td>
    </tr>
    <tr>
      <td>The <font color="blue">unamortized values</font> of other <font color="blue">intangibles</font> are     reviewed if certain <font color="blue">conditions</font> exist</td>
    </tr>
    <tr>
      <td>When we perform <font color="blue">future <font color="blue">impairment</font></font>     tests,  it  is  possible  that the carrying value of goodwill or other     <font color="blue">intangible assets</font> could exceed their implied <font color="blue">fair value</font> and <font color="blue">therefore would</font>     require <font color="blue">adjustment</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">adjustment</font> would result in a charge to operating     income in that period</td>
    </tr>
    <tr>
      <td>Once adjusted, there can be no assurance that there     will not be further <font color="blue">adjustment</font>s for <font color="blue">impairment</font> in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">uncertainty</font>  of  patent and <font color="blue">proprietary</font> <font color="blue">technology</font> protection may     <font color="blue">adversely</font> affect us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on obtaining and maintaining <font color="blue">meaningful</font>     <font color="blue"><font color="blue">patent protection</font> on</font> our <font color="blue">inventions</font>, <font color="blue">technologies</font> and <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>   a substantial majority of our <font color="blue">POL and Clinics and Small Hospitals </font>revenues     are <font color="blue">attributable</font> to <font color="blue">products without <font color="blue">patent protection</font></font>, our <font color="blue">Genaissance </font>and     Icoria <font color="blue">businesses</font> and related <font color="blue">technologies</font> are more <font color="blue">heavily reliant on such</font>     <font color="blue">patent protection</font> and we will have to <font color="blue">address such issues</font></td>
    </tr>
    <tr>
      <td>Our ability to     compete <font color="blue">effective</font>ly will depend on our ability to develop and maintain     <font color="blue"><font color="blue">proprietary</font> aspects</font> of our <font color="blue">technology</font>, and to operate <font color="blue">without infringing</font> the     <font color="blue"><font color="blue">proprietary</font> rights</font> of others, or to obtain <font color="blue">rights from <font color="blue">third parties</font></font>, if     <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">pending patent <font color="blue">applications</font> may</font> not result in the issuance of     patents</td>
    </tr>
    <tr>
      <td>Our  patent  <font color="blue">applications</font> may not have <font color="blue">priority over others</font>’     <font color="blue">applications</font>, and even if issued, our <font color="blue">patents may</font> not <font color="blue">offer protection</font>     <font color="blue">against <font color="blue">competitors</font> with</font> similar <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">patents issued</font> to us may     be  challenged,  invalidated  or  <font color="blue">circumvented</font>, and the rights created     <font color="blue">thereunder may</font> not <font color="blue">afford us</font> a <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td>We  also  rely  upon  <font color="blue">trade secrets</font>, technical know-how and continuing     <font color="blue">inventions</font> to develop and maintain our <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>Others may     <font color="blue">independently</font> develop <font color="blue">substantially equivalent <font color="blue">proprietary</font></font> information and     <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our <font color="blue">trade secrets</font> or disclose our     <font color="blue">technology</font> and we may not be able to protect <font color="blue">meaningful</font>ly our <font color="blue">trade secrets</font>,     or be capable of protecting our rights to our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We seek to     protect our <font color="blue">technology</font> and patents, in part, by <font color="blue"><font color="blue">confidential</font>ity</font> <font color="blue">agreements</font>     with  our  employees  and  <font color="blue">contractors</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">employees may breach</font> their     <font color="blue"><font color="blue">confidential</font>ity</font>  <font color="blue">agreements</font>  and  these <font color="blue">agreements</font> may not protect our     <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>If we are unable to protect <font color="blue">effective</font>ly our <font color="blue"><font color="blue">intellectual</font> property</font>, we may     not  be  able  to  operate  our business and <font color="blue"><font color="blue">third parties</font> may use</font> our     <font color="blue">technology</font>,  both  of <font color="blue">which <font color="blue">would impair</font></font> our ability to compete in our     markets</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in <font color="blue">significant</font> part on our ability to obtain and     maintain <font color="blue">meaningful</font> <font color="blue">patent protection</font> for certain of our <font color="blue">technologies</font> and     <font color="blue">products throughout</font> the world</td>
    </tr>
    <tr>
      <td>Patent law relating to the scope of claims in     the <font color="blue">technology</font> fields in which we will operate is <font color="blue">still evolving</font></td>
    </tr>
    <tr>
      <td>The degree     of <font color="blue">future protection</font> for our <font color="blue"><font color="blue">proprietary</font> rights</font> is uncertain</td>
    </tr>
    <tr>
      <td>We will rely     on patents to protect a <font color="blue">significant</font> part of our <font color="blue"><font color="blue">intellectual</font> property</font> and to     enhance our <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>However, our <font color="blue">presently pending</font> or future     patent <font color="blue">applications</font> may not <font color="blue">issue as patents</font>, and any patent <font color="blue">previously</font>     issued  to us or our <font color="blue">subsidiaries</font> may be challenged, invalidated, held     unenforceable or                                        -34-       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font><font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>Furthermore, the claims in patents which have been issued to     us or our <font color="blue">subsidiaries</font> or which may be issued to us in the <font color="blue">future may</font> not be     <font color="blue">sufficiently</font>  broad  to <font color="blue">prevent <font color="blue">third parties</font> from</font> producing competing     products similar to our products</td>
    </tr>
    <tr>
      <td>In addition, the laws of <font color="blue">various foreign</font>     countries in which we plan to <font color="blue">compete may</font> not protect our <font color="blue">intellectual</font>     property to the <font color="blue">same extent as</font> do the laws of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If we fail     to obtain adequate <font color="blue">patent protection</font> for our <font color="blue">proprietary</font> <font color="blue">technology</font>, our     ability to be <font color="blue"><font color="blue">commercially</font> <font color="blue">competitive</font> will</font> be <font color="blue"><font color="blue">materially</font> impaired</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">life science companies</font> are <font color="blue">generally uncertain</font> and     <font color="blue">involve complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>Our business could be hurt by     any of the following:       •   our <font color="blue">pending patent <font color="blue">applications</font> may</font> not result in <font color="blue">issued patents</font>;         •   the claims of any issued <font color="blue">patents may</font> not provide <font color="blue">meaningful</font>     protection;          •     we  may  be <font color="blue">unsuccessful</font> in developing <font color="blue">additional</font> <font color="blue">proprietary</font>     <font color="blue">technologies</font> that are patentable;         •   our <font color="blue">patents may</font> not provide a basis for <font color="blue"><font color="blue">commercially</font> viable products</font>     or <font color="blue">provide us with</font> any <font color="blue"><font color="blue">competitive</font> advantage</font>s and may be <font color="blue">challenged by third</font>     parties; and         •   <font color="blue">others may</font> have patents that relate to our <font color="blue">technology</font> or business</td>
    </tr>
    <tr>
      <td>Third parties have filed, and in the future are likely to file, patent     <font color="blue">applications</font>  covering  <font color="blue">biomarkers</font> and related methods that our <font color="blue">Icoria     </font>subsidiary  has  developed or may develop or <font color="blue">technology</font> upon which our     <font color="blue">technology</font> platform depends</td>
    </tr>
    <tr>
      <td>If patent offices issue patents on these patent     <font color="blue">applications</font> and we wish to use the <font color="blue">biomarkers</font> or <font color="blue">technology</font>, we would need     to obtain <font color="blue">licenses from <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td>However, we might not be able to     obtain any <font color="blue">such license on <font color="blue">commercially</font></font> favorable terms, if at all, and if     we do not obtain these licenses, we might be <font color="blue">prevented from using certain</font>     <font color="blue">technologies</font> or taking <font color="blue">certain products</font> to market</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">patent protection</font>, we <font color="blue">will also rely on protection</font> of trade     secrets, know-how and <font color="blue">confidential</font> and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>To maintain     the  <font color="blue"><font color="blue">confidential</font>ity</font>  of trade-secrets and <font color="blue">proprietary</font> information, we     <font color="blue">generally seek</font> to enter into <font color="blue"><font color="blue">confidential</font>ity</font> <font color="blue">agreements</font> with our employees,     <font color="blue">consultants</font> and <font color="blue">strategic partners</font> upon the <font color="blue">commencement</font> of a <font color="blue">relationship</font></td>
    </tr>
    <tr>
      <td>However, we may not obtain these <font color="blue">agreements</font> in all <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>In the     event  of  <font color="blue">unauthorized</font>  use  or <font color="blue">disclosure</font> of this information, these     <font color="blue">agreements</font>, even if obtained, may not provide <font color="blue">meaningful</font> protection for our     <font color="blue">trade secrets</font> or other <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>In addition, adequate     <font color="blue">remedies may</font> not exist in the event of <font color="blue">unauthorized</font> use or <font color="blue">disclosure</font> of     this  information</td>
    </tr>
    <tr>
      <td>The loss or exposure of our <font color="blue">trade secrets</font> and other     <font color="blue">proprietary</font> information <font color="blue">would impair</font> its <font color="blue"><font color="blue">competitive</font> advantage</font>s and could     have a material adverse effect on our operating results, <font color="blue">financial condition</font>     and <font color="blue">future growth prospects</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">third parties</font> make or file claims of <font color="blue"><font color="blue">intellectual</font> property</font> infringement     <font color="blue">against us</font>, or <font color="blue">otherwise seek</font> to establish their <font color="blue"><font color="blue">intellectual</font> property</font>     rights, we may have to spend time and money in response and cease some of     our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> claim that we are employing their <font color="blue">proprietary</font> <font color="blue">technology</font>     <font color="blue">without authorization</font> or that we are <font color="blue">infringing on</font> their patents</td>
    </tr>
    <tr>
      <td>We could     incur substantial costs and diversion of <font color="blue">management</font> and <font color="blue">technical personnel</font>     in <font color="blue">defending against</font> any of these claims</td>
    </tr>
    <tr>
      <td>Furthermore, parties making claims     <font color="blue">against us</font> may be able to obtain injunctive or other <font color="blue">equitable relief which</font>     could <font color="blue">effective</font>ly block our ability to further develop, <font color="blue">commercialize</font> and     <font color="blue">sell products</font></td>
    </tr>
    <tr>
      <td>In the event of a successful claim of infringement, courts     may order us to pay damages and obtain one or more <font color="blue">licenses from third</font>     parties</td>
    </tr>
    <tr>
      <td>We may not be able to obtain these <font color="blue">licenses at</font> a <font color="blue">reasonable cost</font>,     if at all</td>
    </tr>
    <tr>
      <td>If we were sued for <font color="blue">product liability</font>, we could face substantial <font color="blue">liabilities</font>     that may exceed our resources</td>
    </tr>
    <tr>
      <td>We may be held liable if any product we develop, or any <font color="blue">product which</font> is     made using our <font color="blue">technologies</font>, causes injury or is <font color="blue">found unsuitable during</font>     product testing, <font color="blue">manufacturing</font>, marketing, sale or use</td>
    </tr>
    <tr>
      <td>These risks are     inherent in the <font color="blue">development</font> of chemical, agricultural, pharmaceutical, and     other <font color="blue">such <font color="blue">healthcare products</font></font> and related                                        -35-       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font><font color="blue">methodologies</font></td>
    </tr>
    <tr>
      <td>If we choose to obtain <font color="blue">product liability</font> insurance but cannot     obtain <font color="blue">sufficient insurance coverage at</font> an acceptable cost or otherwise     protect against potential <font color="blue">product liability</font> claims, the <font color="blue">commercialization</font> of     products that we or our <font color="blue">commercial partners</font> develop may be prevented or     inhibited</td>
    </tr>
    <tr>
      <td>If we are sued for any injury caused by our products, such     <font color="blue">liability could</font> have a material adverse effect on our business and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any product that we, or our <font color="blue">commercial partners</font> may develop using the gene     function, metabolomics, or biomarker information we provide, may be subject     to a lengthy and uncertain <font color="blue">government</font> <font color="blue">regulatory</font> process that may not result     in  the  <font color="blue">necessary</font> approvals, may delay the <font color="blue">commercialization</font> of these     products or may be costly, any of <font color="blue">which could seriously reduce</font> our revenues     or exceed our <font color="blue">financial ability</font> to <font color="blue">meet such <font color="blue">obligations</font></font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">new products</font> that we or our <font color="blue">commercial partners</font> develop will     likely undergo an extensive <font color="blue">regulatory</font> <font color="blue">review process</font> in the <font color="blue">United States</font>     by the Food and Drug Administration or USDA, and by <font color="blue">regulators</font> in other     countries before it can be marketed or sold</td>
    </tr>
    <tr>
      <td>For example, the FDA must     approve any drug, <font color="blue">diagnostic</font> or <font color="blue">biologic product</font> before it can be marketed     in  the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Genetic <font color="blue">tests offered by</font> the <font color="blue">company may</font> not be     subject to this review</td>
    </tr>
    <tr>
      <td>This <font color="blue">review process</font> can take many years and require     substantial expense</td>
    </tr>
    <tr>
      <td>In the future, we and our <font color="blue">commercial partners</font> may also     be required to submit pre-market information <font color="blue">to the FDA </font><font color="blue">about food</font> developed     through bio<font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Adverse <font color="blue">publicity could lead</font> to <font color="blue">greater regulation</font>     and  <font color="blue">trade <font color="blue">restrictions</font> on imports</font> and exports of <font color="blue">genetically modified</font>     products</td>
    </tr>
    <tr>
      <td>Changes in the policies of US and foreign <font color="blue">regulatory</font> bodies     could increase the time required to obtain <font color="blue">regulatory</font> approval for each new     product</td>
    </tr>
    <tr>
      <td>Our efforts to date have <font color="blue">been primarily</font> limited to identifying targets</td>
    </tr>
    <tr>
      <td>If     <font color="blue">regulators</font> approve any products that we or our <font color="blue">commercial partners</font> develop,     the <font color="blue">approval may impose <font color="blue">limitation</font>s on</font> the uses for which a <font color="blue">product may</font> be     marketed</td>
    </tr>
    <tr>
      <td><font color="blue">Regulators </font>may require the submission of post-market launch     information about a product after approving it, and <font color="blue">may impose <font color="blue">restrictions</font></font>,     including  banning the <font color="blue">continued sale</font> of the product, if they discover     <font color="blue">problems with</font> the product or its <font color="blue"><font color="blue">manufacture</font>r</font></td>
    </tr>
    <tr>
      <td>If  we  are  unable  to develop new and <font color="blue">enhanced products</font> that achieve     widespread market <font color="blue">acceptance</font>, we may be unable to recoup product <font color="blue">development</font>     costs, and our revenues and <font color="blue">earnings may decline</font></td>
    </tr>
    <tr>
      <td>Our  future  <font color="blue">success depends on</font> our ability to <font color="blue">broadly market existing</font>     <font color="blue">technologies</font>, products, and services, and to develop and <font color="blue">introduce new</font>     product and <font color="blue">service offerings</font> and grow our business in each of the POLs,     blood analysis <font color="blue">instrumentation</font>, <font color="blue">diagnostic</font> assays DNA-based <font color="blue">diagnostic</font> and     <font color="blue"><font color="blue">therapeutic</font> products</font>, and human <font color="blue">biomarkers</font> and <font color="blue">agriculture genomics markets</font></td>
    </tr>
    <tr>
      <td>We expect to commit substantial resources to developing <font color="blue">new products</font> and     services,  as  well as to <font color="blue">continue marketing</font> the <font color="blue">existing products</font> and     services</td>
    </tr>
    <tr>
      <td>If the market for these products and services does not develop as     anticipated, or demand for our current product and <font color="blue">service offerings</font> does     not  grow  or  grows more slowly than we expect, we will have expended     substantial resources and capital without realizing sufficient revenue, and     our business and operating results could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We operate in a very <font color="blue"><font color="blue">competitive</font> environment</font></td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">encounter intense <font color="blue">competition</font> from</font> a number of companies that     <font color="blue">offer products</font> in our <font color="blue">targeted application areas</font></td>
    </tr>
    <tr>
      <td>We anticipate that our     <font color="blue">competitors</font> in these <font color="blue">areas will</font> include:       •   <font color="blue">health care</font> and other companies that <font color="blue">manufacture</font> laboratory-based     tests and <font color="blue">analyzers</font>;         •   <font color="blue">diagnostic</font> and <font color="blue">pharmaceutical companies</font>;         •   <font color="blue">molecular services</font> business;         •   companies developing drug discovery <font color="blue">technologies</font>;         •   companies developing molecular <font color="blue">diagnostic</font> and <font color="blue">genetic tests</font>; and         •   companies developing point-of-care <font color="blue">diagnostic</font> and <font color="blue">genetic tests</font></td>
    </tr>
    <tr>
      <td>-36-       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font>If we are successful in developing products in these areas, we will face     <font color="blue">competition</font>  <font color="blue">from established companies</font> and numerous <font color="blue">development</font>-stage     companies  that  <font color="blue">continually</font>  enter  these markets</td>
    </tr>
    <tr>
      <td>In many instances,     <font color="blue">competitors</font> have <font color="blue">substantially greater financial</font>, technical, research and     other resources and larger, more established marketing, sales, <font color="blue">distribution</font>     and <font color="blue">service organizations than us</font></td>
    </tr>
    <tr>
      <td>Moreover, these <font color="blue">competitors</font> may offer     <font color="blue">broader <font color="blue">product line</font>s</font> and have <font color="blue">greater name recognition than us</font> and may     <font color="blue">offer <font color="blue">discounts</font> as</font> a <font color="blue"><font color="blue">competitive</font> tactic</font></td>
    </tr>
    <tr>
      <td>In addition, several <font color="blue">development</font>-stage companies are currently making or     developing products that <font color="blue">compete with</font> or will <font color="blue">compete with</font> our potential     products</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may succeed in developing, obtaining <font color="blue">approval from</font> the     FDA,  or marketing <font color="blue">technologies</font> or products that are more <font color="blue">effective</font> or     <font color="blue">commercially</font> attractive than our current or <font color="blue">potential products</font> or that     render  our  <font color="blue">technologies</font>  and current or <font color="blue">potential products</font> obsolete</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may also develop <font color="blue">proprietary</font> positions that <font color="blue">may prevent us from</font>     <font color="blue">successfully commercializing products</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully integrate</font> companies that we acquire in     the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to <font color="blue">continually</font> enhance and     broaden our <font color="blue">product offerings</font> in response to changing <font color="blue">technologies</font>, customer     demands  and  <font color="blue">competitive</font>  pressures</td>
    </tr>
    <tr>
      <td>From time to time we may pursue     <font color="blue">acquisition</font>s of <font color="blue">businesses</font> that <font color="blue">complement</font> or expand our existing business,     including <font color="blue">acquisition</font>s that could be material in size and scope</td>
    </tr>
    <tr>
      <td>Any future <font color="blue">acquisition</font>s involve various risks, including:       •   <font color="blue">difficult</font>ies in <font color="blue">integrating</font> the <font color="blue">operations</font>, <font color="blue">technologies</font> and products     of the acquired company;          •    the risk of diverting <font color="blue">management</font>’s attention from normal daily     <font color="blue">operations</font> of the business;          •     potential <font color="blue">difficult</font>ies in completing projects <font color="blue">associated with</font>     in-process research and <font color="blue">development</font>;         •   risks of <font color="blue">entering markets</font> in which we have no or limited <font color="blue">direct prior</font>     experience  and where <font color="blue">competitors</font> in <font color="blue">such markets</font> have <font color="blue">stronger market</font>     positions;         •   <font color="blue">initial dependence on unfamiliar supply chains</font> or <font color="blue">relatively</font> small     <font color="blue">supply partners</font>;         •   insufficient revenues to offset increased expenses <font color="blue">associated with</font> the     <font color="blue">acquisition</font>; and         •   the <font color="blue">potential loss</font> of <font color="blue">key employees</font> of the acquired company</td>
    </tr>
    <tr>
      <td>Our ownership is <font color="blue">concentrated among</font> a small number of <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our  ownership  is  <font color="blue">concentrated among</font> a small number of <font color="blue">stockholders</font>,     including Randal J Kirk, our Chairman, Mr</td>
    </tr>
    <tr>
      <td>Kirk’s <font color="blue">affiliates</font>, and Israel M     Stein, MD, our Executive Vice Chairman and Acting Chief Financial Officer</td>
    </tr>
    <tr>
      <td><font color="blue">Together  </font>with  Dr</td>
    </tr>
    <tr>
      <td>Kirk’s  <font color="blue">affiliates</font> hold     <font color="blue">approximately</font> 43dtta7prca of our outstanding <font color="blue">common stock</font> as of June 16, 2006,     after giving effect to the recently completed <font color="blue"><font color="blue">private equity</font> placement</font>     <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>Kirk’s  <font color="blue">affiliates</font> have a     controlling block of our <font color="blue">outstanding stock</font> and are able to exert substantial     control  <font color="blue">over various corporate matters</font></td>
    </tr>
    <tr>
      <td><font color="blue">Notwithstanding </font><font color="blue">such control</font>,     Mr</td>
    </tr>
    <tr>
      <td><font color="blue">Kirk and Dr</font></td>
    </tr>
    <tr>
      <td>Stein, <font color="blue">as directors</font> of <font color="blue">Clinical Data</font>, have <font color="blue">fiduciary duties</font>     under  <font color="blue">Delaware </font>law to all our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Delaware </font><font color="blue">law also imposes</font>     certain <font color="blue">additional</font> <font color="blue">fiduciary duties</font> on Dr</td>
    </tr>
    <tr>
      <td>Stein by virtue of his status as     an officer of <font color="blue">Clinical Data</font></td>
    </tr>
    <tr>
      <td>-37-       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>We <font color="blue">will continue</font> to shift our Icoria subsidiary’s traditional business model     away from agriculture-based research and areas of <font color="blue">historical revenue</font></td>
    </tr>
    <tr>
      <td>Icoria recently shifted towards the <font color="blue">healthcare industry</font> and the <font color="blue">therapeutic</font>     fields of obesity, liver disease and diabetes, which is a <font color="blue">fundamental</font> shift     <font color="blue">away from known</font> and <font color="blue">historical areas</font> of <font color="blue">revenue generation</font></td>
    </tr>
    <tr>
      <td>There has not     been  sufficient  time  to <font color="blue">discover whether</font> Icoria has been or will be     successful in this effort</td>
    </tr>
    <tr>
      <td>Our     Icoria subsidiary’s belief that the <font color="blue">potential market</font> for <font color="blue">healthcare products</font>     and services is better for its long-term business prospects, rather than the     strategy of using agriculture-based contracts to generate revenues, may be     <font color="blue"><font color="blue">based on</font> data</font> and <font color="blue">assumptions</font> that are flawed, we may not have the financial     ability  or  expertise  to <font color="blue">effectuate</font> this shift, and the costs of the     transition  may be <font color="blue">prohibitive</font></td>
    </tr>
    <tr>
      <td>Our belief that it can obtain material     revenues  from any healthcare partnerships, <font color="blue">agreements</font>, <font color="blue">discoveries</font> or     <font color="blue">contracts may</font> be incorrect</td>
    </tr>
    <tr>
      <td>Our Icoria business <font color="blue">exposes us</font> to risks of <font color="blue">environmental</font> <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>Our Icoria subsidiary’s research and <font color="blue">development</font> activities involve the     <font color="blue">controlled use</font> of hazardous materials, chemicals and toxic compounds which     could  expose  us  to  risks  of  <font color="blue"><font color="blue">accident</font>al</font>  <font color="blue">contamination</font>, events of     non-<font color="blue">compliance with</font> <font color="blue"><font color="blue">environmental</font> laws</font>, <font color="blue">regulatory</font> <font color="blue">enforcement</font> and claims     related to <font color="blue">personal injury</font> and <font color="blue">property damage</font></td>
    </tr>
    <tr>
      <td>If an <font color="blue">accident</font> occurred or     if we were to discover <font color="blue">contamination</font> caused by prior <font color="blue">operations</font>, we could be     liable for cleanup <font color="blue">obligations</font>, damages or fines, and any <font color="blue">liability could</font>     exceed our resources</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">environmental</font> laws</font> of many <font color="blue">jurisdictions impose actual</font> and potential     <font color="blue">obligations</font> on us to <font color="blue">remediate contaminated sites</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">environmental</font>     remediation <font color="blue">obligations</font> could exceed our resources</td>
    </tr>
    <tr>
      <td>Stricter <font color="blue">environmental</font>,     safety  and  <font color="blue">health laws</font> and <font color="blue">enforcement</font> policies also could result in     substantial costs and <font color="blue">liabilities</font> to us, and could subject our handling,     <font color="blue">manufacture</font>, use, reuse or disposal of substances or <font color="blue">pollutants</font> to more     rigorous  scrutiny  than  is currently the case</td>
    </tr>
    <tr>
      <td>Consequently, ongoing     <font color="blue">compliance with</font> these laws could result in <font color="blue">significant</font> capital <font color="blue">expenditure</font>s,     as well as other costs and <font color="blue">liabilities</font>, which could <font color="blue">materially</font> <font color="blue">adversely</font>     affect our Company</td>
    </tr>
    <tr>
      <td>If  we choose to acquire new and <font color="blue">complement</font>ary <font color="blue">businesses</font>, products or     <font color="blue">technologies</font>,  we  may be unable to complete such <font color="blue">acquisition</font>(s) or to     integrate an acquired business or <font color="blue">technology</font> in a cost-<font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our ability to <font color="blue">continually</font> enhance and broaden our     <font color="blue">product offerings</font> in response to changing <font color="blue">technologies</font>, customer demands and     <font color="blue">competitive</font> pressures</td>
    </tr>
    <tr>
      <td>To this end, instead of developing them, from time to     time  we  have  acquired  and may yet acquire <font color="blue">additional</font> <font color="blue">complement</font>ary     <font color="blue">businesses</font>,  products,  or  <font color="blue">technologies</font> or <font color="blue">may enter into cooperative</font>     ventures</td>
    </tr>
    <tr>
      <td>We do not know if we will be able to complete such <font color="blue">acquisition</font>s,     or whether we will be able to <font color="blue">successfully integrate</font> an acquired business,     operate it profitably, or retain its <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td><font color="blue">Integrating </font>any acquired     business, product or <font color="blue">technology</font>, or any <font color="blue">venture into which</font> we may enter,     could  be  expensive  and time-consuming and <font color="blue">could disrupt</font> our ongoing     business, distract our <font color="blue">management</font> and <font color="blue">materially</font> and <font color="blue">adversely</font> affect our     <font color="blue">cash flows</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are required to <font color="blue">seek financing</font> for an <font color="blue">acquisition</font> or other venture, or     to enhance our working capital, we may not be able to obtain such <font color="blue">additional</font>     <font color="blue">financing on</font> acceptable terms</td>
    </tr>
    <tr>
      <td>In order to finance any <font color="blue">acquisition</font>s or other ventures, or to enhance our     working capital, we may need to raise <font color="blue">additional</font> funds through public or     <font color="blue">private equity</font> or <font color="blue">debt financings</font></td>
    </tr>
    <tr>
      <td>In that event, we could be required to     obtain <font color="blue">financing on</font> terms that are unfavorable to us and, in the case of     equity or equity-linked financing, on terms that may result in dilution to     our  existing <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot sell</font> our securities or obtain     <font color="blue">additional</font> <font color="blue">financing on</font> acceptable terms, we may not be able to:                                        -38-       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>  •   expand our <font color="blue">product line</font> and <font color="blue">service offerings</font>;         •   hire and <font color="blue">train new staff</font> ;         •   increase our sales and <font color="blue">marketing presence</font> in existing and <font color="blue">new markets</font>;     or         •   respond to <font color="blue">competitive</font> pressures or unanticipated <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Our failure to do any of these <font color="blue">things could <font color="blue">seriously harm</font></font> our financial     <font color="blue">condition by preventing us from</font> being able to <font color="blue">effective</font>ly grow our business     or to take advantage of new business <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent upon</font> an asset-based line of credit for certain of our     working capital</td>
    </tr>
    <tr>
      <td>That loan imposes <font color="blue">conditions</font> that could <font color="blue">adversely</font> affect     us</td>
    </tr>
    <tr>
      <td>We used an asset-based line of credit to finance a portion of the assets we     <font color="blue">purchased from</font> Elan</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>31, 2006, we had <font color="blue">outstanding borrowings</font> of     dlra4dtta0 million under that line</td>
    </tr>
    <tr>
      <td>This debt may <font color="blue">adversely</font> affect our future     <font color="blue">operations</font> in <font color="blue">several important ways</font>, including the following:       •   our ability to obtain <font color="blue">additional</font> financing may be impaired;         •   if we do not satisfy the <font color="blue">financial covenants</font> in the <font color="blue">loan agreement</font>, we     would be in <font color="blue">default under</font> our <font color="blue">loan agreement</font> and be required to <font color="blue">immediately</font>     <font color="blue">repay outstanding loan balances</font>; and         •   because we do not have a fixed rate of interest for our loans, rising     <font color="blue">interest rates will increase</font> our <font color="blue">interest costs</font> and reduce our earnings</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">international</font>  <font color="blue">operations</font> and <font color="blue">sales expose us</font> to <font color="blue">foreign currency</font>     <font color="blue">exchange rate <font color="blue">fluctuation risks</font></font></td>
    </tr>
    <tr>
      <td>The costs of <font color="blue">importation</font> of <font color="blue">instruments</font> and other products are subject to     <font color="blue">foreign currency</font> <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>In fiscal 2006, sales to <font color="blue">customers outside</font>     the <font color="blue">United States</font> accounted for <font color="blue">approximately</font> 49dtta2prca of our revenues</td>
    </tr>
    <tr>
      <td>We     anticipate  that  <font color="blue">international</font>  sales  <font color="blue">will continue</font> to account for a     <font color="blue">significant</font> portion of our revenues</td>
    </tr>
    <tr>
      <td>Most of our sales to <font color="blue">international</font>     <font color="blue"><font color="blue">distributor</font>s</font> are <font color="blue">denominated</font> in Euros</td>
    </tr>
    <tr>
      <td>To the extent that our sales and     operating expenses are <font color="blue">denominated</font> in foreign currencies, our operating     results may be affected by changes in exchange rates</td>
    </tr>
    <tr>
      <td>We cannot predict     <font color="blue">whether such gains</font> and <font color="blue">losses will</font> be material, nor can we predict the     effect of <font color="blue">exchange rate <font color="blue">fluctuations</font> on</font> our future operating results</td>
    </tr>
    <tr>
      <td>We     sometimes engage in limited, <font color="blue">transaction</font> specific, <font color="blue">foreign currency</font> hedging     <font color="blue">transaction</font>s to reduce our risk, but we <font color="blue">cannot assure</font> you that any such     hedging  <font color="blue">transaction</font> will allow us to avoid any <font color="blue">currency exchange rate</font>     <font color="blue">fluctuation risks</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> <font color="blue">operations</font> and <font color="blue">sales expose us</font> to political and economic     risks</td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> <font color="blue">operations</font> and reliance on <font color="blue">international</font> <font color="blue">sales expose us</font>     to <font color="blue">foreign political</font> and <font color="blue">economic risks</font>, including:       •   <font color="blue">regulatory</font> approvals;         •   import and export license <font color="blue">requirements</font> and <font color="blue">restrictions</font>;         •   <font color="blue">disruptions</font> in <font color="blue">international</font> transport or delivery;         •   <font color="blue">difficult</font>ies in <font color="blue">collecting receivables</font>; and         •   <font color="blue">potentially</font> adverse tax consequences</td>
    </tr>
    <tr>
      <td>If any of these <font color="blue">risks materializes</font>, our <font color="blue">international</font> sales could decrease     and our foreign <font color="blue">operations</font> could suffer</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent upon</font> certain key personnel</td>
    </tr>
    <tr>
      <td>We  are highly <font color="blue">dependent upon</font> the <font color="blue">principal members</font> of our <font color="blue">management</font>,     <font color="blue">engineering</font> and <font color="blue">scientific staff</font>, including Andrew J Fromkin, our President     and Chief Executive Officer, and Israel M Stein, MD, our Executive Vice                                        -39-       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font>Chairman and Acting Chief Financial Officer</td>
    </tr>
    <tr>
      <td>The loss of the service of any     of  these  persons  could  seriously  harm our product <font color="blue">development</font> and     <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>Our products require <font color="blue"><font color="blue">government</font> approval</font> to be marketed</td>
    </tr>
    <tr>
      <td>We have obtained or are in the process of obtaining all <font color="blue">necessary</font> <font color="blue">government</font>     approvals  to market our <font color="blue">current products</font> in the <font color="blue">United States</font> and the     <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td>However, we <font color="blue">will likely</font> need to obtain approval of certain     European <font color="blue">regulatory</font> bodies and the FDA to market many of the <font color="blue">new products</font>     that  we may develop or obtain the rights to distribute</td>
    </tr>
    <tr>
      <td>Domestically,     certain of our products are <font color="blue">classified as medical devices under</font> the Food,     Drug and Cosmetics Act</td>
    </tr>
    <tr>
      <td>As such, if and when these products are offered for     sale in the <font color="blue">United States</font>, these <font color="blue">products will</font> be subject to continuing     regulation and <font color="blue">oversight by</font> the FDA The cost of obtaining <font color="blue">such approvals</font>     may be high and the process lengthy, with no assurance that <font color="blue">such approvals</font>     will be obtained</td>
    </tr>
    <tr>
      <td>To date, neither the FDA nor the European medical <font color="blue">regulatory</font> bodies have     developed industry-wide performance standards with respect to the safety and     <font color="blue">effective</font>ness of the products that we <font color="blue">presently market</font></td>
    </tr>
    <tr>
      <td>Although we intend     to <font color="blue">use reasonable efforts</font> to <font color="blue">comply with</font> <font color="blue">international</font> standards, when and     if developed, there can be no assurance that our <font color="blue">products as currently</font>     configured  will be in compliance</td>
    </tr>
    <tr>
      <td>Any failure to receive and maintain     approvals  for  our  products, or non<font color="blue">compliance with</font> any <font color="blue">international</font>     <font color="blue">performance standards promulgated</font> in the future, could have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>Furthermore, any material change in the     <font color="blue">existing rules</font> and <font color="blue">regulations</font> or the adoption of any new <font color="blue">regulations</font> could     <font color="blue">adversely</font> affect us</td>
    </tr>
    <tr>
      <td>Physician’s office <font color="blue">laboratories</font> must <font color="blue">comply with</font> <font color="blue">government</font> <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Clinical  </font><font color="blue">laboratories</font>,  including  POLs,  are  subject to <font color="blue">significant</font>     <font color="blue"><font color="blue">government</font>al regulation at</font> the Federal, state and <font color="blue">sometimes local levels</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> govern licensure and operation of clinical <font color="blue">laboratories</font>,     payment for laboratory services, <font color="blue">health care</font> fraud and abuse, security and     <font color="blue"><font color="blue">confidential</font>ity</font> of health information, and <font color="blue">environmental</font> and <font color="blue">occupational</font>     safety</td>
    </tr>
    <tr>
      <td>CLIA extended Federal oversight to virtually all clinical <font color="blue">laboratories</font> by     requiring  that  they  be  <font color="blue">certified by</font> the Federal <font color="blue">government</font> or by a     Federally-approved  <font color="blue">accreditation</font>  agency</td>
    </tr>
    <tr>
      <td>Pursuant to CLIA, clinical     <font color="blue">laboratories</font> must meet quality assurance, <font color="blue">quality control</font> and personnel     standards</td>
    </tr>
    <tr>
      <td><font color="blue">Laboratories </font><font color="blue">also must undergo proficiency testing</font> and are     subject to <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td><font color="blue">Standards </font>for testing under CLIA are <font color="blue">based on</font> the     <font color="blue">complexity</font>  of  the  tests performed by the laboratory, with all tests     classified as either high <font color="blue">complexity</font>, moderate <font color="blue">complexity</font>, or waived</td>
    </tr>
    <tr>
      <td>We     specialize in providing moderate <font color="blue">complexity</font> test products and consulting     services  for  <font color="blue">such testing</font>, and POLs <font color="blue">which purchase such products</font> and     services  also  require CLIA <font color="blue">certificates</font> to perform <font color="blue">such testing</font></td>
    </tr>
    <tr>
      <td>Any     material change in the <font color="blue">existing rules</font> and <font color="blue">regulations</font> or the adoption of any     new <font color="blue">regulations</font> could <font color="blue">adversely</font> affect us by making our <font color="blue">customers less</font>     willing or able to remain in the business</td>
    </tr>
    <tr>
      <td>The sanction for failure to     <font color="blue">comply with</font> CLIA <font color="blue">requirements</font> may be suspension, revocation or <font color="blue">limitation</font> of     a laboratory’s CLIA certificate, which is <font color="blue">necessary</font> to conduct business, as     well as <font color="blue">significant</font> fines and/or criminal penalties</td>
    </tr>
    <tr>
      <td>The loss or suspension     of a license, imposition of a fine or other penalties, or future changes in     the CLIA law or <font color="blue">regulations</font> (or <font color="blue">interpretation</font> of the law or <font color="blue">regulations</font>)     related  to  smaller  <font color="blue">labs could</font> have a material adverse effect on our     business</td>
    </tr>
    <tr>
      <td>We are <font color="blue">further regulated by</font> the HIPAA, as amended</td>
    </tr>
    <tr>
      <td>HIPAA includes standards     of practice for the protection of the privacy of <font color="blue">individually identifiable</font>     health information</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> HIPAA could result in <font color="blue">significant</font>     fines and <font color="blue">criminal liability</font></td>
    </tr>
    <tr>
      <td>In addition, future changes in Federal, state     or  local <font color="blue">regulations</font> or policies (or in the <font color="blue">interpretation</font> of current     <font color="blue">regulations</font>)  could  <font color="blue">adversely</font> affect our ability to <font color="blue">sell products</font> and     services to POLs</td>
    </tr>
    <tr>
      <td>Physician’s office <font color="blue">laboratories</font> are dependent on third-party payers</td>
    </tr>
    <tr>
      <td>-40-       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font>Future  changes  in  Federal,  state  and local <font color="blue">regulations</font> (or in the     <font color="blue">interpretation</font> of current <font color="blue">regulations</font>) affecting <font color="blue">government</font> payment for     <font color="blue">clinical laboratory testing could</font> have a material adverse effect on the     <font color="blue">profitability</font> of POLs and would <font color="blue">adversely</font> affect the sale of our products     and services</td>
    </tr>
    <tr>
      <td>We are unable to predict what type of <font color="blue">legislation</font>, if any,     will be <font color="blue">enacted into law</font></td>
    </tr>
    <tr>
      <td>In addition, changes in rates of <font color="blue">reimbursement</font>     made <font color="blue">by private insurers</font> and other third-party payers may have a similar     <font color="blue">detrimental</font> effect on our business</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font>problems or <font color="blue">delays could</font> result in <font color="blue">lost revenue</font></td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">manufacture</font> most</font> of our <font color="blue">instruments</font> in Dieren, The Netherlands and most     of our reagents in Brea, California</td>
    </tr>
    <tr>
      <td>Other products are <font color="blue"><font color="blue">manufacture</font>d</font> in     <font color="blue">Italy and France </font>on an OEM basis</td>
    </tr>
    <tr>
      <td>These <font color="blue">manufacturing</font> processes are complex     and, as a result, any <font color="blue">prolonged disruption</font> in our <font color="blue">manufacturing</font> <font color="blue">operations</font>     or the <font color="blue">manufacturing</font> <font color="blue">operations</font> of our third party <font color="blue"><font color="blue">manufacture</font>r</font>s could     <font color="blue">seriously harm</font> our ability to satisfy our customer order <font color="blue">deadlines</font></td>
    </tr>
    <tr>
      <td>If we     cannot deliver our systems in a <font color="blue">timely manner</font>, our revenues <font color="blue">will likely</font>     suffer</td>
    </tr>
    <tr>
      <td>As we develop <font color="blue">new products</font>, we <font color="blue">must transition</font> the <font color="blue">manufacture</font> of each new     <font color="blue">product from</font> the <font color="blue">development</font> stage to <font color="blue">commercial product</font>ion</td>
    </tr>
    <tr>
      <td>We cannot     <font color="blue">predict whether</font> we will be able to complete <font color="blue">such transitions on</font> a timely     basis and with <font color="blue">commercially</font> <font color="blue">reasonable cost</font>s</td>
    </tr>
    <tr>
      <td>We also <font color="blue">cannot assure</font> that     <font color="blue">manufacturing</font> or <font color="blue">quality control</font> problems will not arise as we attempt to     scale-up our production for any future <font color="blue">new products</font> or that we can scale-up     <font color="blue">manufacturing</font> and <font color="blue">quality control</font> in a <font color="blue">timely manner</font> or at <font color="blue">commercially</font>     <font color="blue">reasonable cost</font>s</td>
    </tr>
    <tr>
      <td>If we are unable to consistently <font color="blue">manufacture</font> our products     on a <font color="blue">timely basis due</font> to these or other factors, our <font color="blue"><font color="blue">product sales</font> will</font>     decline</td>
    </tr>
    <tr>
      <td>Intense <font color="blue">competition</font> could reduce our market share or limit our ability to     <font color="blue">increase market</font> share, <font color="blue">which could harm</font> our <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">medical products industry</font> is <font color="blue">rapidly evolving</font> and <font color="blue">development</font>s are     expected to <font color="blue">continue at</font> a rapid pace</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in this industry, which     includes  our medical <font color="blue">instrumentation</font>, reagent and consulting services     <font color="blue">businesses</font>,  is  intense  and  expected  to  increase as <font color="blue">new products</font>,     <font color="blue">technologies</font> and services become available and new <font color="blue">competitors</font> enter the     market</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> in the <font color="blue">United States</font>, Europe and Pacific-Asia are     numerous and include, <font color="blue">among others</font>, large, multi-national <font color="blue">diagnostic</font> testing     and <font color="blue">medical products companies</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success depends upon</font> maintaining     a <font color="blue"><font color="blue">competitive</font> position</font> in the <font color="blue">development</font> of products, <font color="blue">technologies</font> and     services in our areas of focus in POLs and smaller clinical <font color="blue">laboratories</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may:       •   develop <font color="blue">technologies</font>, products and services that are more <font color="blue">effective</font>     than our products or services, or that render our <font color="blue">technologies</font>, products or     <font color="blue">services obsolete</font> or non<font color="blue">competitive</font>;         •   obtain <font color="blue">patent protection</font> or other <font color="blue"><font color="blue">intellectual</font> property</font> rights that     <font color="blue">would prevent us from</font> developing our <font color="blue">potential products</font>; or         •   obtain <font color="blue">regulatory</font> approval for the <font color="blue">commercialization</font> of their products     more rapidly or <font color="blue">effective</font>ly than we do</td>
    </tr>
    <tr>
      <td>Also,  the  <font color="blue">possibility</font>  of <font color="blue"><font color="blue">intellectual</font> property</font> rights disputes with     <font color="blue">competitors</font> holding domestic and foreign patent and other <font color="blue">intellectual</font>     property  rights  may  limit  or <font color="blue">delay expansion possibilities</font> for our     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>In addition, many of our existing or potential <font color="blue">competitors</font> have     or  may have <font color="blue">substantially greater financial</font> and <font color="blue">managerial resources</font>,     research  and  <font color="blue">development</font>  <font color="blue">capabilities</font>, and clinical, <font color="blue">manufacturing</font>,     <font color="blue">regulatory</font> and marketing experience</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue"><font color="blue">distributor</font>s</font> for <font color="blue">product sales</font> and support</td>
    </tr>
    <tr>
      <td>Our  sales are primarily made through <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>We often rely upon     <font color="blue"><font color="blue">distributor</font>s</font> to <font color="blue">provide customer support</font> to the ultimate end users of our     products</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">success depends on</font> the <font color="blue">continued sale</font>s and     customer  support  efforts  of our network of <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>The use of     <font color="blue"><font color="blue">distributor</font>s</font> involves certain risks, including risks that <font color="blue"><font color="blue">distributor</font>s</font> will     not <font color="blue">effective</font>ly sell or support our products, or will be unable to satisfy     financial <font color="blue">obligations</font> to us and cease their <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any reduction, delay     or loss of <font color="blue">orders from</font> our <font color="blue">significant</font> <font color="blue"><font color="blue">distributor</font>s</font> could harm our business</td>
    </tr>
    <tr>
      <td><font color="blue">There                                        </font>-41-       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>can be no assurance that we <font color="blue">will continue</font> to engage qualified <font color="blue"><font color="blue">distributor</font>s</font>,     and  the  failure to do so could have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">distributor</font> <font color="blue">agreements</font> provide for the <font color="blue">distributor</font> to <font color="blue">purchase products</font>     from  us  at standard prices that are <font color="blue">updated periodically</font></td>
    </tr>
    <tr>
      <td>We have no     <font color="blue">obligations</font>  to  the  <font color="blue"><font color="blue">distributor</font>s</font>  after  the  product is shipped</td>
    </tr>
    <tr>
      <td>We     <font color="blue">occasionally</font> offer <font color="blue"><font color="blue">distributor</font>s</font> special pricing on selected products to     <font color="blue">promote sales</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">discounts</font> and <font color="blue">special pricing provisions</font> are recognized     <font color="blue">as reductions</font> of <font color="blue">revenue as</font> we ship our product to the <font color="blue">distributor</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">occasionally</font>  offer  incentive  <font color="blue">programs directly</font> to our <font color="blue"><font color="blue">distributor</font>s</font>’     <font color="blue">salespeople</font></td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> will be <font color="blue">adversely</font> affected if we fail to realize     the full value of our <font color="blue">intangible assets</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>31, 2006, our <font color="blue">total assets</font> included <font color="blue">approximately</font> dlra51dtta8 million     of net <font color="blue">intangible assets</font></td>
    </tr>
    <tr>
      <td>Net <font color="blue">intangible assets</font> consist principally of     (i) goodwill  <font color="blue">associated with</font> <font color="blue">acquisition</font>s; (ii) costs <font color="blue">associated with</font>     <font color="blue"><font color="blue">capitalized</font> software</font>; and (iii) purchased <font color="blue">intangibles</font> consisting of customer     <font color="blue"><font color="blue">relationship</font>s</font>,  net of <font color="blue">accumulated amortization</font></td>
    </tr>
    <tr>
      <td>Goodwill is not being     <font color="blue">amortized while</font> the purchased <font color="blue">intangibles</font> are being <font color="blue">amortized over</font> their     estimated <font color="blue">useful lives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Amortization </font>of <font color="blue"><font color="blue">capitalized</font> software</font> is provided     over the estimated useful life of the product, which is <font color="blue">generally four</font>     years</td>
    </tr>
    <tr>
      <td><font color="blue">Goodwill  </font>is  tested,  at  a minimum, on an <font color="blue">annual basis using</font>     <font color="blue">December </font>31^st as the <font color="blue">annual measurement date</font> for potential <font color="blue">impairment</font> by     comparing the carrying value to the <font color="blue">fair market value</font> of the reporting unit     to which the goodwill is assigned; as of March 31, 2006, <font color="blue">approximately</font>     dlra6dtta3 million of the goodwill is assigned to the POL segment, dlra1dtta2 million to     the clinics and small hospitals segment and the remainder is assigned to the     <font color="blue">molecular services</font> segment</td>
    </tr>
    <tr>
      <td><font color="blue">Amortizable </font><font color="blue">intangibles</font>, including <font color="blue">capitalized</font>     software, are subject to <font color="blue">impairment</font> reviews when there are <font color="blue">indication</font>s of     <font color="blue">impairment</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">fair value</font> of our recorded <font color="blue">intangibles</font> can be <font color="blue">impacted by economic</font>     <font color="blue">conditions</font>,  market  risks, and the <font color="blue">volatility</font> in the markets in which     <font color="blue"><font color="blue">Clinical Data</font> </font>and its customers operate</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">fair value</font> could result     in <font color="blue">future <font color="blue">impairment</font></font> charges if the <font color="blue">fair value</font> of the reporting units or     <font color="blue">asset groups</font> to which these long-lived assets are associated are determined     to be less than the carrying value of <font color="blue">such assets</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">annual <font color="blue">assessment</font></font> of     goodwill or the periodic <font color="blue">impairment</font> testing considerations may result in     <font color="blue">impairment</font> charges or <font color="blue">additional</font> intangible asset write-offs, respectively,     which could <font color="blue">adversely</font> affect our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31,     2005, the most recent evaluation date, there was no <font color="blue">impairment</font> of goodwill</td>
    </tr>
    <tr>
      <td>Additionally, there were <font color="blue">no indicators</font> of <font color="blue">impairment</font> that would require an     <font color="blue">assessment</font> of the <font color="blue">impairment</font> of our other <font color="blue">intangible assets</font></td>
    </tr>
    <tr>
      <td>Risk factors relating to <font color="blue">Clinical Data</font>’s <font color="blue">common stock</font>     The price of our <font color="blue">common stock</font> is volatile and could cause investors to lose     a substantial part of their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market</font> in general and the <font color="blue">stock prices</font> of <font color="blue">technology</font> companies in     particular, experience <font color="blue">volatility</font>, which has <font color="blue">often been unrelated</font> to the     operating performance of any <font color="blue">particular company</font> or companies</td>
    </tr>
    <tr>
      <td>Our common     stock  is <font color="blue">lightly traded</font> and its <font color="blue">price could decline regardless</font> of our     company’s  actual  operating  performance</td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font><font color="blue">also could lose</font> a     substantial part of their <font color="blue">investment</font> as a result of industry or market-based     <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>If a more active public market for our <font color="blue">common stock</font> is not     created, it may be <font color="blue">difficult</font> for <font color="blue">stockholders</font> to resell their shares</td>
    </tr>
    <tr>
      <td>A     number of <font color="blue">additional</font> factors also could cause the <font color="blue">prevailing market prices</font>     of our <font color="blue">common stock</font> to fluctuate <font color="blue"><font color="blue">significant</font>ly</font> and could <font color="blue">adversely</font> impact     such  prices and the ability of our company to raise <font color="blue">additional</font> equity     capital</td>
    </tr>
    <tr>
      <td>Such factors include but are not limited to the following:       •   the timing of our <font color="blue">announcements</font> or of our <font color="blue">competitors</font>’ <font color="blue">announcements</font>     regarding <font color="blue">significant</font> products, contracts or <font color="blue">acquisition</font>s;         •   <font color="blue">variations</font> in results of <font color="blue">operations</font>;         •   changes in earnings estimates <font color="blue">by securities analysts</font>;         •   <font color="blue">general economic</font> and market <font color="blue">conditions</font>; and                                        -42-       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>  •   sales of substantial amounts of our <font color="blue">common stock</font> into the public     market, or the <font color="blue">perception</font> that <font color="blue">such sales might</font> occur</td>
    </tr>
    <tr>
      <td>If  the  average  closing  price  of  our <font color="blue">common stock</font> were to decline     <font color="blue"><font color="blue">significant</font>ly</font>,  we  may  be  required to issue in excess of 20prca of our     outstanding capital stock upon <font color="blue">conversion</font> <font color="blue">of the <font color="blue">Series A Preferred Stock </font></font>we     issued to the <font color="blue"><font color="blue">preferred stock</font>holder</font> of <font color="blue">Genaissance </font>in our <font color="blue">recent merger with</font>     that company</td>
    </tr>
    <tr>
      <td>In our <font color="blue">recent merger with</font> Genaissance, we issued 484cmam070 shares of our     <font color="blue">Series A Preferred Stock </font>to the holder of all of the <font color="blue">preferred stock</font> of     Genaissance</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>31, 2006, the holder of our Series A Preferred     Stock has converted 250cmam000 shares of our <font color="blue">Series A Preferred Stock </font>into     shares of our <font color="blue">common stock</font>, leaving 234cmam070 shares of our Series A Preferred     Stock outstanding</td>
    </tr>
    <tr>
      <td>Our outstanding <font color="blue">preferred stock</font> is <font color="blue">initially convertible</font>     into  234cmam070 shares of our <font color="blue">common stock</font>, or <font color="blue">approximately</font> 2dtta7prca of our     <font color="blue">outstanding capital stock as</font> of March 31, 2006</td>
    </tr>
    <tr>
      <td>However, if our preferred     <font color="blue">stock remains outstanding until</font> October 6, 2008, then and thereafter, the     <font color="blue">conversion</font> price of the <font color="blue">preferred stock</font> will begin to float <font color="blue">based on</font> the     <font color="blue">public market price</font> of our <font color="blue">common stock</font>, subject to a minimum <font color="blue">conversion</font>     factor  of one share of <font color="blue">preferred stock</font> for one share of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">According </font>to the terms of our Series A Preferred Stock, after the third     <font color="blue">anniversary</font> of the closing date of the <font color="blue">Genaissance </font>merger, on any given date     of <font color="blue">conversion</font>, the <font color="blue">conversion</font> price will be equal to the average closing bid     price of our <font color="blue">common stock</font> for the 10 consecutive trading days prior to such     date of <font color="blue">conversion</font></td>
    </tr>
    <tr>
      <td>As a result, if the average closing bid price of the our     <font color="blue">common stock</font> were to decline, the number of shares of our <font color="blue">common stock</font> into     which our <font color="blue">Series A Preferred Stock </font>is <font color="blue">then convertible would increase</font></td>
    </tr>
    <tr>
      <td>If     the average closing bid price of our <font color="blue">common stock</font> declines enough, it is     possible that we would have to issue a number of shares of our <font color="blue">common stock</font>     upon <font color="blue">conversion</font> of our series A <font color="blue">preferred stock</font> that would be <font color="blue">greater than</font>     20prca of our then-outstanding capital stock</td>
    </tr>
    <tr>
      <td>Such an event does not require     <font color="blue">additional</font> stockholder approval, would have the effect of diluting your     ownership <font color="blue">of the Company </font>and could result in the <font color="blue"><font color="blue">preferred stock</font>holder</font>     <font color="blue">exercising control over certain corporate decisions</font> of the Company, which it     <font color="blue">previously</font> did not have the ability to control or influence</td>
    </tr>
  </tbody>
</table>